Compare Brookfield Infrastructure Partners LP (BIP) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs GeneDx Holdings Corp — how do they compare? Brookfield Infrastructure Partners LP trades at $39.63 (market cap $18.10B), while GeneDx Holdings Corp trades at $81.89 (market cap $2.44B). The key difference: Brookfield Infrastructure Partners LP is far larger — about 7.4× GeneDx Holdings Corp's market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| BIP | WGS | |
|---|---|---|
Market Cap | $18.10B | $2.44B |
Sector | Industrials | Technology |
52-Week High | $42.62 | $167.51 |
52-Week Low | $29.81 | $34.51 |
Enterprise Value | $77.05B | $2.48B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.97, up 5.24% over 24 hours, with a bullish technical signal from moving averages. The stock shows strong analyst support with 13 buy ratings and a consensus price target of $44.67. Recent financials indicate revenue growth to $25.1 billion in 2026, though net income declined to $652 million. The company maintains a dividend yield with recent payouts of $0.46 per share and is undergoing corporate simplification to enhance shareholder value.
BIP presents a mixed outlook; attractive valuation metrics like EV/EBITDA of 6.97 and P/S of 0.72 suggest upside, but consecutive earnings misses and declining profitability margins pose risks. Investors may benefit from infrastructure demand and high dividend yields, yet should monitor execution on earnings targets and debt levels, with institutional sentiment leaning bullish amid macroeconomic uncertainties.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
